argenx agrees to acquire Unnatural Products for up to $1.15 billion to expand peptide drug discovery

argenx has agreed to acquire macrocyclic peptide specialist Unnatural Products in a transaction worth up to $1.15 billion, combining a substantial upfront payment with development-dependent milestones to expand beyond antibody therapeutics.

The definitive agreement announced on 9 November 2026 provides for argenx to acquire the remaining shares of Unnatural Products for $550 million in upfront cash and up to $595 million in contingent development and regulatory milestones, following more than two years of collaboration and argenx's existing minority investment.

The acquisition would add Unnatural Products' macrocyclic peptide discovery capabilities to argenx's antibody engineering platform, supporting potential oral and long-acting immunology medicines, while completion is expected by year-end 2026 subject to customary conditions and the headline $1.15 billion represents maximum potential rather than guaranteed consideration.

Field	Content
Article Type	Deals
Acquirer	argenx
Target Company	Unnatural Products
Deal Type	Definitive acquisition agreement
Announcement Date	9 November 2026
Transaction Status	Announced; not yet completed
Maximum Potential Transaction Value	Approximately $1.15 billion
Upfront Cash Consideration	$550 million
Contingent Milestone Consideration	Up to $595 million
Milestone Categories	Development and regulatory milestones
Milestone Payment Status	Contingent on future achievements
Existing Ownership	argenx already holds a minority stake
Acquisition Scope	Remaining shares of Unnatural Products
Prior Relationship	Research collaboration lasting more than two years
Target Technology	Macrocyclic peptide discovery platform
Drug Discovery Modality	Macrocyclic peptides
Potential Product Characteristics	Oral and long-acting therapeutic candidates
Therapeutic Focus	Immunology
Acquirer Existing Technology	Antibody engineering capabilities
Strategic Objective	Expand therapeutic discovery capabilities beyond antibody-based medicines
Technology Integration	Combine macrocyclic peptide discovery with argenx's existing therapeutic development expertise
Expected Closing	By year-end 2026
Closing Conditions	Customary transaction closing conditions
Regulatory Approval Status	No new medicine approval associated with the transaction
What Happened	argenx agreed to acquire Unnatural Products for upfront cash and contingent milestone payments.
Why It Matters	The transaction provides argenx with a complementary discovery platform that could support new immunology medicines with differentiated administration profiles.
Strategic Significance	Expands argenx's drug discovery capabilities into macrocyclic peptides while building on an established collaboration.
Financial Clarification	The $1.15 billion maximum includes $595 million of contingent milestones; only $550 million is specified as upfront cash.
Transaction Distinction	Definitive agreement rather than a completed acquisition
Key Takeaway	argenx is pursuing a major peptide technology acquisition with $550 million upfront and substantial performance-dependent consideration.
What to Watch	Transaction completion, platform integration, new peptide candidates, clinical development milestones and future milestone payments.
Primary Source	argenx
Primary Source URL	https://argenx.com/news/2026/press-release-3398049
Relevant Date	9 November 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com